

Table 19.8
Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	31	31	31	-	-	-
1970-1973 ^a	-	-	-	41	39	43	-	-	-
1975-1977 ^b	46.5	45.5	47.5	46.8	46.3	47.3	48.4	42.6	54.8 ^g
1978-1980 ^b	47.9	46.1	49.8	47.9	46.2	49.5	51.1	46.9	56.7
1981-1983 ^b	50.5	50.2	50.9	50.8	50.5	51.1	49.4	49.0	49.8
1984-1986 ^b	51.6	50.0	53.3	52.0	50.6	53.6	46.7	44.5	49.6
1987-1989 ^b	50.9	47.6	54.9	51.3	48.1	55.3	46.1	41.7	51.2
1990-1992 ^b	50.7	46.7	55.8	51.6	47.6	56.5	42.0	38.1	47.5
1993-1995 ^b	52.5	48.7	57.4	53.2	49.7	57.6	42.0	35.9	53.7
1996-1998 ^b	58.9	57.0	61.0	59.5	57.6	61.6	54.2	52.7	56.4
1999-2003 ^b	66.3	64.2	68.7	67.4	65.7	69.4	59.0	54.0	64.9
2004-2010 ^b	71.4 ^f	70.1 ^f	72.8 ^f	72.5 ^f	71.5 ^f	73.6 ^f	63.0 ^f	58.8 ^f	67.7 ^f
5-Year Period Survival (Percent) ^{cd}									
2010	70.4	69.1	71.9	70.7	69.6	72.1	64.7	61.4	68.7
Stage Distribution (%) 2004-2010 ^{ce}									
All Stages									
Number of cases	92,653	49,978	42,675	77,541	41,843	35,698	7,475	4,057	3,418
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	28	27	29	28	27	29	28	25	31
Regional	15	15	16	15	15	16	15	14	15
Distant	49	51	47	50	51	48	51	54	47
Unstaged	8	7	8	7	7	8	7	6	7
5-Year Relative Survival (Percent), 2004-2010 ^c									
Age at Diagnosis:									
Ages <45	79.4	76.7	83.6	81.4	78.7	86.0	65.9	62.7	70.8
Ages 45-54	77.8	74.5	82.6	79.6	76.4	84.3	63.0	58.5	70.0
Ages 55-64	75.2	72.3	79.0	76.3	73.6	79.8	65.0	59.8	71.7
Ages 65-74	70.3	67.4	73.5	70.9	68.2	73.9	63.6	53.8	71.3
Ages 75+	53.1	52.3	53.7	53.7	52.8	54.4	44.9	44.8	44.4
Ages <65	77.2	74.3	81.3	78.6	75.9	82.6	64.8	60.6	70.9
Ages 65+	60.9	59.8	62.0	61.4	60.3	62.3	55.5	50.6	58.7
Stage ^e :									
All Stages	69.3	68.0	70.9	69.9	68.9	71.2	62.2	58.4	66.6
Localized	81.6	81.3	82.0	82.1	82.1	82.1	76.3	72.4	80.0
Regional	72.9	72.3	73.5	73.5	73.4	73.6	67.2	63.9	70.4
Distant	61.6	60.1	63.6	62.7	61.2	64.5	53.2	50.6	56.7
Unstaged	66.9	66.0	67.8	65.6	64.8	66.5	61.0	56.7	65.3

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2011.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Based on follow-up of patients into 2011.

^d Period survival provides a 2010 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2007-2009: 0-1 year survival), (2006-2008: 1-2 year survival), (2005-2007: 2-3 year survival), (2004-2006: 3-4 year survival), (2003-2005: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2004-2010 is statistically significant (p<.05).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.